No abstract

No abstract

It has been previously described that COVID-19 treatment with tocilizumab can cause reactivation of CMV leading to colitis. However, COVID-19-associated CMV duodenitis is exceedingly rare, with limited cases reported thus far. In one report, a 73-year-old man with severe COVID-19 respiratory failure developed abdominal pain in the recovery phase and was noted to have CMV-induced duodenitis and pancreatitis. However, this patient had recent diagnosis of primary cutaneous large B-cell lymphoma and was thus immunosuppressed. 1 This is the first case describing COVID-19-associated CMV duodenitis in a previously immunocompetent host. Moreover, this is only the second reported case of CMV duodenitis in any COVID-19 patient. We suggest any critically ill patient with COVID-19 and gastrointestinal bleeding should be assessed for infectious etiologies such as CMV. (Figure).